Frontiers in Medicine (Jan 2025)

Oral ATP treatment in alternating hemiplegia of childhood: a case report and review

  • Marco Carrozzi,
  • Maria Elisa Morelli,
  • Mario Cirino,
  • Alessandra Maestro,
  • Gilda Paternuosto,
  • Giulia Benericetti,
  • Giada Bennati,
  • Maura Bin,
  • Anna Flamigni,
  • Federico Pigato,
  • Natalia Maximova,
  • Egidio Barbi,
  • Egidio Barbi,
  • Davide Zanon

DOI
https://doi.org/10.3389/fmed.2024.1433217
Journal volume & issue
Vol. 11

Abstract

Read online

Alternating hemiplegia of childhood (AHC) is a rare neurological disorder that usually manifests before 18 months of age and is characterized by recurrent, alternating episodes of hemiparesis with variable frequency and can last from a few minutes to several days. We present a case of AHC in a little girl carrying a sporadic mutation in the ATP1A3 gene (p.Glu815Lys) refractory to flunarizine and non-compliant to topiramate due to adverse effects treated with oral compound of adenosine-5′-triphosphate (ATP) capsules. Outcome was evaluated through the follow-up and side effects and safety were monitored regularly. Compounded drug showed effectiveness and safety. Indeed, during the four-year follow-up, with the dose of adenosine-5′-triphosphate gradually increasing up to 21 mg/kg, the patient showed a substantial benefit in controlling the frequency and duration of hemiplegic episodes and an improvement in neurological deterioration.

Keywords